精华制药
(002349)
| 流通市值：60.98亿 | | | 总市值：61.14亿 |
| 流通股本：8.12亿 | | | 总股本：8.14亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,511,751,346.97 | 1,119,659,192.47 | 795,349,522.37 | 416,357,917.91 |
| 营业收入 | 1,511,751,346.97 | 1,119,659,192.47 | 795,349,522.37 | 416,357,917.91 |
| 二、营业总成本 | 1,185,197,086.72 | 864,866,529.85 | 591,680,301.7 | 298,578,026.85 |
| 营业成本 | 775,641,663.38 | 575,199,039.79 | 405,568,737.46 | 206,503,914.34 |
| 税金及附加 | 21,304,299.79 | 15,810,393.71 | 10,846,794.16 | 5,696,627.45 |
| 销售费用 | 227,972,947.97 | 164,988,556.88 | 107,721,313.92 | 47,267,598.34 |
| 管理费用 | 118,804,600.3 | 83,863,745.33 | 52,832,928.99 | 26,231,411.51 |
| 研发费用 | 64,619,849.59 | 44,544,568.46 | 28,779,866.14 | 13,215,026.76 |
| 财务费用 | -23,146,274.31 | -19,539,774.32 | -14,069,338.97 | -336,551.55 |
| 其中:利息费用 | 2,573,901.39 | 1,929,809.25 | 1,305,106.38 | 823,029.23 |
| 其中:利息收入 | 23,635,092.97 | 18,416,709.43 | 12,264,507.41 | 3,217,934.12 |
| 加:公允价值变动收益 | 6,832,117.8 | 5,105,353.41 | 2,814,109.58 | 905,983.56 |
| 加:投资收益 | 238,448.3 | -292,446.63 | -606,281.35 | -227,899.57 |
| 资产处置收益 | -87,053.73 | -74,944.54 | -58,912.28 | 50,101.08 |
| 资产减值损失(新) | -7,949,316.79 | -3,409,697.44 | -2,040,105.75 | -1,464,030.18 |
| 信用减值损失(新) | -2,028,986.71 | -1,455,348.6 | -2,931,415.29 | -2,271,622.69 |
| 其他收益 | 7,294,715.48 | 2,386,702.42 | 1,586,680.43 | 1,021,094.72 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 330,854,184.6 | 257,052,281.24 | 202,433,296.01 | 115,793,517.98 |
| 加:营业外收入 | 1,086,904.14 | 807,318.31 | 811,096.35 | 422,029.41 |
| 减:营业外支出 | 2,245,889.68 | 857,510.27 | 49,239.35 | 43,308.27 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 329,695,199.06 | 257,002,089.28 | 203,195,153.01 | 116,172,239.12 |
| 减:所得税费用 | 53,228,550.69 | 36,871,071.25 | 29,630,280.71 | 17,130,968.98 |
| 六、净利润 | 276,466,648.37 | 220,131,018.03 | 173,564,872.3 | 99,041,270.14 |
| 持续经营净利润 | 276,466,648.37 | 220,131,018.03 | 173,564,872.3 | 99,041,270.14 |
| 归属于母公司股东的净利润 | 247,697,195.98 | 195,349,254.74 | 154,607,331.58 | 87,671,328.3 |
| 少数股东损益 | 28,769,452.39 | 24,781,763.29 | 18,957,540.72 | 11,369,941.84 |
| (一)基本每股收益 | 0.3 | 0.24 | 0.19 | 0.11 |
| (二)稀释每股收益 | 0.3 | 0.24 | 0.19 | 0.11 |
| 八、其他综合收益 | -3,222,911.66 | - | - | - |
| 归属于母公司股东的其他综合收益 | -3,222,911.66 | - | - | - |
| 九、综合收益总额 | 273,243,736.71 | 220,131,018.03 | 173,564,872.3 | 99,041,270.14 |
| 归属于母公司股东的综合收益总额 | 244,474,284.32 | 195,349,254.74 | 154,607,331.58 | 87,671,328.3 |
| 归属于少数股东的综合收益总额 | 28,769,452.39 | 24,781,763.29 | 18,957,540.72 | 11,369,941.84 |
| 公告日期 | 2024-04-19 | 2023-10-30 | 2023-08-26 | 2023-04-29 |
| 审计意见(境内) | 标准无保留意见 | | | |